Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220)

Ann Oncol 2017; 28: iv72-iv83 (doi:10.1093/annonc/mdx220) Under the section "Adjuvant treatment" Adjuvant treatment Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of risk are defined: intermediate- and high-risk patients. Is replaced with: Adjuvant treatment (Table 3) Two classes of risk are defined: intermediate- and high-risk patients. In "Table 5. Summary of recommendations" Adjuvant treatment • Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3). • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A]. Is replaced with: Adjuvant treatment • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].